GE HealthCare Technologies Inc. (NASDAQ:GEHC) shares are up on Friday, buoyed by positive sector performance and recent FDA clearances.
FDA Approves MRI Technology
The FDA has recently approved GE HealthCare’s next-generation SIGNA MRI technology, which is designed to enhance precision imaging and clinical efficiency. This milestone is significant as it includes the SIGNA Sprint with Freelium technology, aiming to reduce helium dependency—a critical advancement in making MRI technology more sustainable and cost-effective.
The new SIGNA Bolt 3T MRI scanner, part of this FDA clearance, is noted for its powerful performance and sustainable design. It promises up to a 65% reduction in peak power demand and a 34% reduction in minimum equipment room space, showcasing GE HealthCare’s commitment to innovation and environmental sustainability.
Stock Trading Above Moving Averages
GE HealthCare Technologies is currently performing well against its moving averages, indicating a bullish trend. The stock is trading 4.9% above its 20-day SMA and 6.6% above its 100-day SMA. Over the past 12 months, however, the stock has seen a decline of 8.59%, reflecting some challenges despite recent gains.
The technical indicators reveal mixed signals. The RSI stands at 56.28, suggesting a neutral market momentum, while the MACD, which is above its signal line, indicates bullish momentum. This combination points to potential upward movement, albeit with caution due to the stock’s recent volatility.
Optimistic Expectations For Upcoming Earnings
Looking further out, the next major catalyst for the stock arrives with the April 29, 2026 earnings report. As GE HealthCare Technologies prepares for this date, investors are keenly watching how these advancements might translate into financial performance.
- EPS Estimate: $1.06 (Up from $1.01 YoY)
- Revenue Estimate: $5.03 Billion (Up from $4.78 Billion YoY)
- Valuation: P/E of 18.2x (Indicates fair valuation)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $93.35. Recent analyst moves include:
- BTIG: Buy (Maintains Target to $91.00) (Feb. 9)
- Barclays: Equal-Weight (Raises Target to $87.00) (Feb. 6)
- Stifel: Buy (Raises Target to $98.00) (Feb. 5)
Stock Trading Slightly Up In Regular Hours
GEHC Price Action: GE HealthCare Techs shares were up 1.48% at $84.24 at the time of publication on Friday, according to Benzinga Pro data.
Image: Shutterstock
